Funding for this research was provided by:
National Science Foundation (1564936)
Office of Postsecondary Education (P200A180092)
Article History
Received: 5 October 2020
Accepted: 13 October 2020
First Online: 30 December 2020
Ethics approval and consent to participate
: The sequencing data analyzed in this manuscript was generated as part of the Phase I clinical trial “Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma” (ClinicalTrials.gov Identifier: NCT02933073), conducted in accordance with FDA and Human Subject Protection regulations under IRB approval from the UConn Health Center. Written informed consent was obtained from all subjects.
: Not applicable.
: ES and JF declare that they have no competing interests. IIM declares that he has a significant financial interest in Truvax Inc., a company developing personalized cancer vaccines.